| Primary information |
|---|
| sequence ID | Seq_2831 |
| Peptide sequence | GLEEELQFSLGSKINV |
| CancerPDF_ID | CancerPDF_ID39, CancerPDF_ID885, CancerPDF_ID1054, CancerPDF_ID9623, |
| PMID | 16896061,19795908,16395409,21533267 |
| Protein Name | Complement C4 precursor,Complement C4-B,Complement C4 precursor,Complement C4-B |
| UniprotKB Entry Name | "CO4A_HUMAN,CO4B_HUMAN",CO4B_HUMAN,CO4A_HUMAN,CO4B_HUMAN |
| Fluid | Serum,Plasma,Serum,Serum |
| M/Z | 1762.87,"881.96, 588.31",1762.87,881.97 |
| Charge | 1,"2, 3",1,2 |
| Mass (in Da) | 1762.92,NA,NA,NA |
| fdr | NA,NA,NA,NA |
| Profiling Technique | MALDI-TOF,LC-MS,MALDI-TOF,LC-MS |
| Peptide Identification technique | Q/TOF MS/MS,MALDI-TOF/TOF,Q/TOF/TOF and LC-MS/MS,LC/MS/MS |
| Quantification Technique | NA,LC-MRM (multiple reaction monitoring),NA,Multiple Reaction Monitoring |
| Labelled/Label Free | Label Free,Labelled,Label Free,Label Free |
| FDR | NA,less than 7%,less than 1 “5,1.49 |
| CancerPDF_ID | CancerPDF_ID39, CancerPDF_ID885, CancerPDF_ID1054, CancerPDF_ID9623, |
| p-Value | 1.00E-05,NA,2.32E-13,NA |
| Software | MASCOT,FlexAnalysis 3.0 and Biotools 3.0 software,MASCOT (v 2.0.04 for Windows),MASCOT |
| Length | 16,16,16,16 |
| Cancer Type | Metastatic thyroid carcinomas,Ductal adenocarcinoma of the pancreas (DAP),"Advanced Prostate, Breast and Bladder cancer",Lung adenocarcinoma |
| Database | NCBI refseq Protein Database,NCBI refseq Protein Database,NCBI refseq Protein Database,Swissprot Database (57.4) |
| Modification | NA,NA,NA,NA |
| Number of Patients | 40 metastatic thyroid carcinoma patients and 40 normal for training phase and 10 metastatic thyroid carcinoma and 10 normal individuals for independent validation,"42 normal, 28 patients","Advanced prostate (n = 32), breast (n = 21), and bladder (n = 20) cancer, 33 healthy in training test set, In validation set 41 independent serum samples from patients with advanced prostate cancer (prostate 2 [PR2])",62 lung adenocarcinoma and 30 healthy control |
| Regulation | NA,NA,"For bladder (Lower) and for breast (Higher) Differential ion intensity in cancer compare to normal with Ratio of median intensity (patients/Controls) =1.62, 0.01 and 3.16 in prostate, bladder and breast cancer respectively","Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" |
| Validation | Independent validation,NA,Independent validation,MRM-based validation of 19 candidates |
| Sensitivity | 95% on independent dataset,NA,97.5% on independent validation dataset,NA |
| Specificity | 95% on independent dataset,NA,NA,NA |
| Accuracy | NA,NA,97.5 % on validation dataset,NA |
| Peptide Atlas | NA |
| IEDB | 462023
|